PYRUKYND

Indicated For

pyruvate kinase (PK) deficiency

About This Medication

# myAgios Patient Assistance Program Patient Guide: How to Get PYRUKYND (mitapivat) at Low or No Cost PYRUKYND (mitapivat) is a prescription medication used to treat pyruvate kinase (PK) deficiency in adults and children 12 years and older, and certain types of thalassemia. The **myAgios Patient Assistance Program** from **Agios Pharmaceuticals** provides free medication to eligible uninsured or underinsured patients, helping you access this important treatment without high costs.[1][2][4] ## About PYRUKYND and Why Assistance Matters PYRUKYND is the first oral therapy approved to help increase hemoglobin levels and reduce the need for blood transfusions in people with PK deficiency, a rare genetic disorder affecting red blood cells. It works by activating an enzyme called pyruvate kinase, which improves red blood cell energy and survival. For patients with non-transfusion-dependent alpha- or beta-thalassemia, it also helps manage anemia.[2][6] Living with PK deficiency or thalassemia can be challenging, with symptoms like fatigue, jaundice, and frequent transfusions. PYRUKYND offers hope, but its cost without insurance can be prohibitive—often tens of thousands per year. That's where the myAgios Patient Assistance Program (PAP) steps in, offering **free prescriptions** to those who qualify, plus support services like education, adherence reminders, and access help.[2][4] This guide walks you through eligibility, application steps, and more, so you can focus on your health. ## Who Qualifies for the Program? The program is designed for **uninsured or underinsured patients** diagnosed with PK deficiency or eligible thalassemia who need financial help. Commercially insured patients may qualify for a separate copay program that reduces costs to $0 per prescription (government-insured patients are ineligible for copay assistance).[2][6] **Key eligibility factors**: - U.S. resident with a valid prescription for PYRUKYND. - Diagnosis of PK deficiency or qualifying thalassemia. - Limited or no insurance coverage. - Financial need (income details reviewed case-by-case).[1][2] ## Income Eligibility Breakdown Specific income thresholds aren't publicly listed; eligibility is determined individually by Patient Support Managers based on household income, expenses, and federal poverty level (FPL) guidelines. They consider your full financial picture for uninsured/underinsured patients.[1][2] Here's a general overview of how PAPs like this often work (call for your personalized assessment): | Household Size | Typical FPL Limit (e.g., 400-500% FPL) | Notes | |---------------|---------------------------------------|-------| | Individual | ~$60,000-$75,000 annually | Exact amount varies; case-by-case review. | | Couple | ~$80,000-$100,000 annually | Includes all household income sources. | | Family of 3 | ~$100,000-$125,000 annually | Proof of income may be requested. | | Family of 4+ | ~$120,000+ annually | Adjusted for family size; contact for details. | *These are illustrative based on common PAP standards—**call (877) 772-4467** for your exact eligibility.* Patient Support Managers provide personalized guidance without strict cutoffs listed online.[1][2] ## Insurance Requirements - **Uninsured**: Fully eligible for free medication.[2] - **Underinsured (commercial/private insurance)**: May qualify for PAP if costs are unaffordable; copay program available separately for $0 copays.[6] - **Government insurance (Medicare, Medicaid, etc.)**: Ineligible for copay assistance; PAP may still apply if underinsured aspects exist—confirm via phone.[2][6] A Coverage Interruption Program offers free 28-day supply (up to 2 refills) for temporary commercial coverage gaps.[2] ## Step-by-Step Application Process Applying is straightforward and free. Your doctor initiates it, but you play a key role. 1. **Discuss with your doctor**: Confirm PYRUKYND is right for you. They'll complete the PYRUKYND Start Form (Enrollment Form) with your details, prescription, and diagnosis.[1][3][4] 2. **Provide your information**: Share patient details like name, DOB, address, phone, email, last 4 SSN digits, insurance info (if any), and caregiver details (optional). Sign the patient/caregiver section for HIPAA consent.[1][3] 3. **Doctor signs and faxes**: Your prescriber signs, dates, and faxes the full form (pages 1-5) to myAgios at **1-800-951-7814**. Or enroll online via myagios.com for auto-processing.[1][2][3] 4. **Call Patient Support**: Dial **(877) 772-4467** (Mon-Fri, 8 AM-8 PM ET) to speak with a Patient Support Manager (PSM). They'll guide enrollment, check eligibility, and coordinate.[1][2][4] 5. **Approval and next steps**: Once processed, medication ships via specialty pharmacy. You'll get education, reminders, and support.[2][4] No online application URL; phone/fax is primary.[1] ## Timeline and Delivery Processing time varies (not specified; typically 1-2 weeks for PAPs). Expect a call from your PSM post-fax for signature/confirmation. Medication is **shipped directly to your home** via a network specialty pharmacy. Monthly check-ins, emails, and webinars help with adherence.[1][2][4] ## Alternatives if Denied or Ineligible - **Copay Program**: For commercial insurance—$0 copay if eligible.[6] - **Coverage Interruption**: Free supply during gaps.[2] - **Independent Foundations**: myAgios connects you (e.g., via enrollment form).[5] - **Other PAPs**: Check PAN Foundation or Patient Access Network. - **Appeal**: Contact PSM to discuss denial reasons and reapply with more docs. - **No biosimilars** available for PYRUKYND.[1] ## Important Disclaimer This guide is for informational purposes based on publicly available program details as of latest info. Eligibility, terms, and availability can change—**always verify with myAgios at (877) 772-4467**. Agios determines eligibility at their discretion. Not medical advice; consult your doctor. Program not for government-insured in copay aspects. Full terms at myagios.com.[1][2][6][8] *Word count: ~950*

Program information last verified: March 30, 2026